FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318903889> ?p ?o ?g. }

• W4318903889 endingPage "392" @default.
• W4318903889 startingPage "392" @default.
• W4318903889 abstract "392 Background: Recently, neoadjuvant chemotherapy has been recognized as a promising strategy to improve the survival of patients with advanced gastric cancer. On the other hand, given the adverse events and treatment cost of chemotherapy, the candidate for NAC should be limited to patients who can benefit from NAC. In fact, as previously reported, the proportion of pathological stage I tumors was 50.4% in cT2N0, 38.7% in cT2N(+), 26.7% in cT3N0, 10.6% in cT3N(+), 9.0% in cT4aN0, and 3.0% in cT4aN(+). Therefore, clinical staging before initiation of treatment is increasingly important for determining therapeutic strategy. However, the long-term survival stratified by the prospectively-determined clinical stage has not been fully investigated. Methods: Between July 2013 and November 2014, the JCOG1302A examined 1260 patients with a clinical diagnosis of cT2/T3/T4, cN0/N1/N2/N3, M0, except for diffuse large tumors like linitis plastica and extensive bulky nodal diseases according to the Japanese Classification of Gastric Carcinoma (3rd English edition). The cT diagnosis was made by upper gastrointestinal endoscopy and comprehensive findings on upper abdominal contrast CT scan with 1 or 5 mm slice thickness. Lymph nodes with a shortest dimension greater than 8 mm or a longest dimension greater than 10 mm were defined as positive for metastasis. In this follow-up study, the survival data by stratifying the clinical staging were evaluated. Results: Among 1260 patients, survival data of 1177 were analyzed. With a median follow-up for 821 surviving patients of 6.0 years, the 5y-OS was 82.1% (95% CI, 77.3-85.9) in cT2 (n=319), 72.7% (68.2-76.6) in cT3 (n=450), 60.0% (54.9-64.7) in cT4a (n=401), and 40.0% (5.2-75.3) in cT4b (n=6), while that was 78.0% (74.2-81.2) in cN0 (n=560), 70.6% (65.4-75.2) in cN1 (n=350), 59.1% (52.5-65.1) in cN2 (n=241), and 28.4% (12.7-46.5) in cN3 (n=26), respectively. When combined with cT and cN, 5y-OS was 83.5% (77.8-87.8) in cT2N0 (n=226), 77.2% (71.0-82.2) in cT3N0 (n=232), 66.8% (56.3-75.2) in cT4aN0 (n=100), 100% in cT4bN0 (n=1), 78.7% (68.6-85.8) in cT2N(+)(n=93), 68.0% (61.1-73.8) in cT3N(+)(n=218), 57.7% (51.7-63.2) in cT4aN(+)(n=301), and 25.0% (0.9-66.5) in cT4bN(+)(n=5). Conclusions: Both the survival and the proportion of overdiagnosis of stage I patients in patients with cT4aN0, categorized as cstage IIB, was almost same as in those cT3N(+) categorized as cstage III. In considering the candidate for further treatment development of NAC with high toxic regime in future, cT3N(+) and cT4aN0 should be considered as equivalent category." @default.
• W4318903889 created "2023-02-03" @default.
• W4318903889 creator A5003130075 @default.
• W4318903889 creator A5004883743 @default.
• W4318903889 creator A5005597709 @default.
• W4318903889 creator A5018087364 @default.
• W4318903889 creator A5022874036 @default.
• W4318903889 creator A5026555298 @default.
• W4318903889 creator A5030748838 @default.
• W4318903889 creator A5032337008 @default.
• W4318903889 creator A5039783762 @default.
• W4318903889 creator A5040552693 @default.
• W4318903889 creator A5042633928 @default.
• W4318903889 creator A5042660442 @default.
• W4318903889 creator A5048511174 @default.
• W4318903889 creator A5051603709 @default.
• W4318903889 creator A5052598485 @default.
• W4318903889 creator A5055693159 @default.
• W4318903889 creator A5077365053 @default.
• W4318903889 creator A5078062326 @default.
• W4318903889 date "2023-02-01" @default.
• W4318903889 modified "2023-09-26" @default.
• W4318903889 title "Survival results by the prospectively determined clinical staging for locally advanced gastric cancer: An ancillary study of JCOG1302A (JCOG1302A2)." @default.
• W4318903889 doi "https://doi.org/10.1200/jco.2023.41.4_suppl.392" @default.
• W4318903889 hasPublicationYear "2023" @default.
• W4318903889 type Work @default.
• W4318903889 citedByCount "0" @default.
• W4318903889 crossrefType "journal-article" @default.
• W4318903889 hasAuthorship W4318903889A5003130075 @default.
• W4318903889 hasAuthorship W4318903889A5004883743 @default.
• W4318903889 hasAuthorship W4318903889A5005597709 @default.
• W4318903889 hasAuthorship W4318903889A5018087364 @default.
• W4318903889 hasAuthorship W4318903889A5022874036 @default.
• W4318903889 hasAuthorship W4318903889A5026555298 @default.
• W4318903889 hasAuthorship W4318903889A5030748838 @default.
• W4318903889 hasAuthorship W4318903889A5032337008 @default.
• W4318903889 hasAuthorship W4318903889A5039783762 @default.
• W4318903889 hasAuthorship W4318903889A5040552693 @default.
• W4318903889 hasAuthorship W4318903889A5042633928 @default.
• W4318903889 hasAuthorship W4318903889A5042660442 @default.
• W4318903889 hasAuthorship W4318903889A5048511174 @default.
• W4318903889 hasAuthorship W4318903889A5051603709 @default.
• W4318903889 hasAuthorship W4318903889A5052598485 @default.
• W4318903889 hasAuthorship W4318903889A5055693159 @default.
• W4318903889 hasAuthorship W4318903889A5077365053 @default.
• W4318903889 hasAuthorship W4318903889A5078062326 @default.
• W4318903889 hasConcept C121608353 @default.
• W4318903889 hasConcept C126322002 @default.
• W4318903889 hasConcept C126838900 @default.
• W4318903889 hasConcept C141071460 @default.
• W4318903889 hasConcept C143998085 @default.
• W4318903889 hasConcept C146357865 @default.
• W4318903889 hasConcept C151730666 @default.
• W4318903889 hasConcept C2776694085 @default.
• W4318903889 hasConcept C2779013556 @default.
• W4318903889 hasConcept C2780611263 @default.
• W4318903889 hasConcept C535046627 @default.
• W4318903889 hasConcept C71924100 @default.
• W4318903889 hasConcept C86803240 @default.
• W4318903889 hasConceptScore W4318903889C121608353 @default.
• W4318903889 hasConceptScore W4318903889C126322002 @default.
• W4318903889 hasConceptScore W4318903889C126838900 @default.
• W4318903889 hasConceptScore W4318903889C141071460 @default.
• W4318903889 hasConceptScore W4318903889C143998085 @default.
• W4318903889 hasConceptScore W4318903889C146357865 @default.
• W4318903889 hasConceptScore W4318903889C151730666 @default.
• W4318903889 hasConceptScore W4318903889C2776694085 @default.
• W4318903889 hasConceptScore W4318903889C2779013556 @default.
• W4318903889 hasConceptScore W4318903889C2780611263 @default.
• W4318903889 hasConceptScore W4318903889C535046627 @default.
• W4318903889 hasConceptScore W4318903889C71924100 @default.
• W4318903889 hasConceptScore W4318903889C86803240 @default.
• W4318903889 hasIssue "4_suppl" @default.
• W4318903889 hasLocation W43189038891 @default.
• W4318903889 hasOpenAccess W4318903889 @default.
• W4318903889 hasPrimaryLocation W43189038891 @default.
• W4318903889 hasRelatedWork W167319750 @default.
• W4318903889 hasRelatedWork W1987468340 @default.
• W4318903889 hasRelatedWork W2039498752 @default.
• W4318903889 hasRelatedWork W2049268294 @default.
• W4318903889 hasRelatedWork W2069774524 @default.
• W4318903889 hasRelatedWork W2083483287 @default.
• W4318903889 hasRelatedWork W2300188460 @default.
• W4318903889 hasRelatedWork W2559850096 @default.
• W4318903889 hasRelatedWork W3143191004 @default.
• W4318903889 hasRelatedWork W4232814199 @default.
• W4318903889 hasVolume "41" @default.
• W4318903889 isParatext "false" @default.
• W4318903889 isRetracted "false" @default.
• W4318903889 workType "article" @default.